AnaptysBio: Upside Constrained By Undifferentiated Data, Legal Uncertainties [Seeking Alpha]
AnaptysBio, Inc. (ANAB)
Last anaptysbio, inc. earnings: 3/2 08:45 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.anaptysbio.com/investor-relations
Company Research
Source: Seeking Alpha
The royalty business, anchored by Jemperli royalties and minimal expenses, offers stable cash flows but faces risk from a pending lawsuit and Sagard repayment. First Tracks, the pipeline entity, is led by rosnilimab—a T-cell depleter with strong translational data but uncertain commercial differentiation in a crowded RA market. Despite positive phase 2 data, dilution risk and lack of clear superiority lead me to rate ANAB as a Hold at current valuation. Dougal Waters/DigitalVision via Getty Images Introduction Given its planned separation into a royalty company and another with a development-stage pipeline, AnaptysBio ( ANAB ) now has to be valued as two different businesses. The royalty business, backed by the billion-dollar blockbuster
Show less
Read more
Impact Snapshot
Event Time:
ANAB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ANAB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ANAB alerts
High impacting AnaptysBio, Inc. news events
Weekly update
A roundup of the hottest topics
ANAB
News
- Assessing AnaptysBio (ANAB) Valuation After New US$100 Million Buyback And Cancelled Equity Offerings [Yahoo! Finance]Yahoo! Finance
- AnaptysBio (ANAB) had its price target raised by Piper Sandler from $67.00 to $95.00. They now have an "overweight" rating on the stock.MarketBeat
- AnaptysBio (ANAB) had its "buy" rating reaffirmed by HC Wainwright. They now have a $66.00 price target on the stock.MarketBeat
- Anaptys Board of Directors Approves Spin-Off of First Tracks Biotherapeutics [Yahoo! Finance]Yahoo! Finance
- Anaptys Board of Directors Approves Spin-Off of First Tracks BiotherapeuticsGlobeNewswire
ANAB
Earnings
- 3/3/26 - Beat
ANAB
Sec Filings
- 4/3/26 - Form 3
- 4/1/26 - Form 4
- 3/30/26 - Form 144
- ANAB's page on the SEC website